AbbVie’s Ibrutinib Approved for Some Pediatric Patients by FDA

The US FDA said AbbVie’s Pharmacyclics was granted approval for Imbruvica (ibrutinib) for pediatric patients above 1 year old with chronic graft versus host disease after failure of one or more lines of systemic therapy.

• Applications for this action were granted priority review; ibrutinib also was granted orphan drug designation

NOTE

• AbbVie Slides After Cutting Sales Outlook on Cancer Drug Decline
• AbbVie Inc. fell 0.4% to $138.41 as of 3:07 p.m. New York time
  • The average 12-month price target of $159.45 is 15.2% above the current price
  • 14 buys, 10 holds, 1 sells

To view the source of this information, ...